These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32871825)

  • 1. Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker for Anaplastic Thyroid Cancer Treated With Lenvatinib.
    Fukuda N; Toda K; Fujiwara YU; Wang X; Ohmoto A; Urasaki T; Hayashi N; Sato Y; Nakano K; Yunokawa M; Ono M; Tomomatsu J; Mitani H; Takahashi S
    In Vivo; 2020; 34(5):2859-2864. PubMed ID: 32871825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential Analysis of Neutrophil-to-lymphocyte Ratio for Differentiated Thyroid Cancer Patients Treated With Lenvatinib.
    Fukuda N; Wang X; Ohmoto A; Urasaki T; Sato Y; Nakano K; Nishizawa M; Yunokawa M; Ono M; Tomomatsu J; Takahashi S
    In Vivo; 2020; 34(2):709-714. PubMed ID: 32111774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib.
    Taylor MH; Takahashi S; Capdevila J; Tahara M; Leboulleux S; Kiyota N; Dutcus CE; Xie R; Robinson B; Sherman S; Habra MA; Elisei R; Wirth LJ
    Thyroid; 2021 Aug; 31(8):1226-1234. PubMed ID: 33637020
    [No Abstract]   [Full Text] [Related]  

  • 5. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
    Dierks C; Seufert J; Aumann K; Ruf J; Klein C; Kiefer S; Rassner M; Boerries M; Zielke A; la Rosee P; Meyer PT; Kroiss M; Weißenberger C; Schumacher T; Metzger P; Weiss H; Smaxwil C; Laubner K; Duyster J; von Bubnoff N; Miething C; Thomusch O
    Thyroid; 2021 Jul; 31(7):1076-1085. PubMed ID: 33509020
    [No Abstract]   [Full Text] [Related]  

  • 6. Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis.
    Kim SY; Kim SM; Kim JW; Lee IJ; Jeon TJ; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2020; 11():599. PubMed ID: 32982983
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Roles of Inflammatory Biomarkers in Radioiodine-Refractory Thyroid Cancer Treated with Lenvatinib.
    Kim CA; Kim M; Jin M; Kim HK; Jeon MJ; Lim DJ; Kim BH; Kang HC; Kim WB; Shin DY; Kim WG
    Endocrinol Metab (Seoul); 2024 Apr; 39(2):334-343. PubMed ID: 38572536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in anaplastic thyroid carcinoma.
    Yamazaki H; Sugino K; Matsuzu K; Masaki C; Akaishi J; Hames K; Tomoda C; Suzuki A; Uruno T; Ohkuwa K; Kitagawa W; Nagahama M; Masuda M; Ito K
    Endocrine; 2020 Oct; 70(1):115-122. PubMed ID: 32307657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer.
    Kim M; Ahn J; Song DE; Yoon JH; Kang HC; Lim DJ; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ; Kim BH
    Endocrine; 2021 Feb; 71(2):427-433. PubMed ID: 32729092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio.
    Xu B; Zhang L; Setoodeh R; Mohanty AS; Landa I; Balzer B; Tiedje V; Ganly I; Dogan S; Fagin JA; Ghossein R
    Endocrine; 2022 Jun; 76(3):612-619. PubMed ID: 35149932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
    Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma.
    Yamazaki H; Iwasaki H; Suganuma N; Toda S; Masudo K; Nakayama H; Rino Y; Masuda M
    Gland Surg; 2021 Mar; 10(3):852-860. PubMed ID: 33842230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study.
    Soll D; Bischoff P; Frisch A; Jensen M; Karadeniz Z; Mogl MT; Horst D; Penzkofer T; Spranger J; Keilholz U; Mai K
    BMC Endocr Disord; 2024 Feb; 24(1):25. PubMed ID: 38383419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer.
    Di Desidero T; Orlandi P; Gentile D; Banchi M; Alì G; Kusmic C; Armanetti P; Cayme GJ; Menichetti L; Fontanini G; Francia G; Bocci G
    Pharmacol Res; 2020 Aug; 158():104920. PubMed ID: 32461187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
    Kawamura Y; Saijo K; Imai H; Ishioka C
    Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and Safety of Lenvatinib for Unresectable Anaplastic Thyroid Cancer].
    Yamazaki H; Shimizu S; Iwasaki H; Yoshida T; Suganuma N; Yamanaka T; Kojima I; Masudo K; Toda S; Nakayama H; Masuda M
    Gan To Kagaku Ryoho; 2017 Aug; 44(8):695-697. PubMed ID: 28860443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Time Series Behavior of Neutrophil-to-Lymphocyte Ratio in Thyroid Cancer Patients on Tyrosine Kinase Inhibitor Therapy.
    Tomoda C; Sugino K; Kitagawa W; Nagahama M; Ito K
    ORL J Otorhinolaryngol Relat Spec; 2021; 83(5):347-353. PubMed ID: 33735904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview.
    Sparano C; Godbert Y; Attard M; Do Cao C; Zerdoud S; Roudaut N; Joly C; Berdelou A; Hadoux J; Lamartina L; Schlumberger M; Leboulleux S
    Endocr Relat Cancer; 2021 Jan; 28(1):15-26. PubMed ID: 33112817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long survival patient of anaplastic thyroid carcinoma treated with lenvatinib.
    Hamamoto T; Kono T; Taruya T; Ishino T; Ueda T; Takeno S
    Auris Nasus Larynx; 2022 Jun; 49(3):515-519. PubMed ID: 33109426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.